• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在一项针对精神分裂症的前瞻性干预研究中,临床结局测量与个人和社会功能表现之间的关系。

Relationship between clinical outcomes measures and personal and social performance functioning in a prospective, interventional study in schizophrenia.

机构信息

Center for Mental Health, Department of Psychiatry and Psychotherapy, University Hospital of Psychiatry Basel, University of Basel, Basel, Switzerland.

Unit of Psychiatry, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

出版信息

Int J Methods Psychiatr Res. 2021 Jun;30(2):e1855. doi: 10.1002/mpr.1855. Epub 2020 Dec 23.

DOI:10.1002/mpr.1855
PMID:33355966
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8170566/
Abstract

OBJECTIVES

To explore clinical and demographic characteristics impacting patient functioning by determining extent of overlap in factors driving change in Personal and Social Performance (PSP) and other clinical outcomes.

METHODS

Post-hoc analysis from a single-arm trial of paliperidone extended release in adult patients with nonacute symptomatic schizophrenia. Psychosocial functioning measures: PSP, Clinical Global Impression-Severity (CGI-S), Positive and Negative Syndrome Scale (PANSS), Short-Form 36 (SF-36), treatment satisfaction, sleep quality/daytime drowsiness, and Extrapyramidal Symptoms Rating Scale.

RESULTS

Highest correlations with PSP total score change included PANSS total score change (Spearman's r = 0.607), PANSS general psychopathology change (r = 0.579), and CGI-S change (r = 0.569). A PSP score change of -32 predicted 90% probability of deterioration in CGI-S (score change of ≥1). The power of PSP change to predict PANSS total score change was lower. Linear stepwise regression demonstrated independent relationships for PSP change and: PANSS total change; CGI-S change; SF-36 Mental Component change; treatment satisfaction at endpoint; PSP at baseline; previous psychiatric hospitalizations. R = 0.55 meant that 45% of PSP variation could not be explained by other clinical outcome measures.

CONCLUSIONS

Psychosocial functioning improvement is important in schizophrenia. PSP may be valuable for assessing functioning; it encompasses psychosocial and clinical factors not measured by other established assessments.

摘要

目的

通过确定影响个人和社会功能(PSP)变化的因素与其他临床结果变化的因素之间的重叠程度,探讨影响患者功能的临床和人口统计学特征。

方法

这是一项帕利哌酮长效制剂治疗成人非急性期症状性精神分裂症的单臂试验的事后分析。心理社会功能测量:PSP、临床总体印象严重度(CGI-S)、阳性和阴性综合征量表(PANSS)、简明 36 健康调查量表(SF-36)、治疗满意度、睡眠质量/白天嗜睡、锥体外系症状评定量表。

结果

与 PSP 总分变化相关性最高的包括 PANSS 总分变化(Spearman's r = 0.607)、PANSS 一般精神病学变化(r = 0.579)和 CGI-S 变化(r = 0.569)。PSP 评分变化-32 预测 CGI-S 恶化的概率为 90%(评分变化≥1)。PSP 变化预测 PANSS 总分变化的能力较低。线性逐步回归显示 PSP 变化与以下因素有独立关系:PANSS 总分变化;CGI-S 变化;SF-36 心理成分变化;终点治疗满意度;PSP 基线值;既往精神科住院治疗。R = 0.55 意味着 45%的 PSP 变化无法用其他临床结果测量来解释。

结论

精神分裂症患者的心理社会功能改善很重要。PSP 可能对评估功能有价值;它包含了其他既定评估未测量的心理社会和临床因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6412/8170566/651a078869d2/MPR-30-e1855-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6412/8170566/d02d37051400/MPR-30-e1855-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6412/8170566/cc7d459c4403/MPR-30-e1855-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6412/8170566/651a078869d2/MPR-30-e1855-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6412/8170566/d02d37051400/MPR-30-e1855-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6412/8170566/cc7d459c4403/MPR-30-e1855-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6412/8170566/651a078869d2/MPR-30-e1855-g003.jpg

相似文献

1
Relationship between clinical outcomes measures and personal and social performance functioning in a prospective, interventional study in schizophrenia.在一项针对精神分裂症的前瞻性干预研究中,临床结局测量与个人和社会功能表现之间的关系。
Int J Methods Psychiatr Res. 2021 Jun;30(2):e1855. doi: 10.1002/mpr.1855. Epub 2020 Dec 23.
2
Association between symptom control and functional improvement in patients with acute schizophrenia: A post hoc analysis of an open-label, single-arm, multi-center study of paliperidone-extended release formulation.急性精神分裂症患者症状控制与功能改善的相关性:一项帕利哌酮缓释制剂开放性、单臂、多中心研究的事后分析。
Psychiatry Res. 2019 Apr;274:301-305. doi: 10.1016/j.psychres.2019.02.036. Epub 2019 Feb 18.
3
Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia.精神分裂症急性症状患者中临床医生评定的个人和社会表现量表的信度、效度及检测变化的能力。
Curr Med Res Opin. 2009 Feb;25(2):325-38. doi: 10.1185/03007990802611919.
4
Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinical Characteristics in Chinese Patients with Schizophrenia.与症状稳定相关的因素使得从每月一次棕榈酸帕利哌酮成功过渡到每三个月一次棕榈酸帕利哌酮:一项事后分析研究了中国精神分裂症患者的临床特征。
CNS Drugs. 2024 Jan;38(1):55-65. doi: 10.1007/s40263-023-01056-x. Epub 2024 Jan 8.
5
Switching to paliperidone extended release in patients with schizophrenia dissatisfied with previous olanzapine treatment: Post hoc analysis of an open-label, prospective study.对先前奥氮平治疗不满意的精神分裂症患者换用帕利哌酮缓释片:一项开放标签前瞻性研究的事后分析
Medicine (Baltimore). 2019 Jan;98(3):e13688. doi: 10.1097/MD.0000000000013688.
6
Treatment of acute schizophrenia with paliperidone ER: predictors for treatment response and benzodiazepine use.帕利哌酮长效注射剂治疗急性精神分裂症:预测治疗反应和苯二氮䓬类药物使用的因素。
Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:207-12. doi: 10.1016/j.pnpbp.2013.09.015. Epub 2013 Oct 2.
7
Clinical effectiveness and resource utilization of paliperidone ER for schizophrenia: Pharmacoepidemiologic International Longitudinal Antipsychotic Registry (PILAR).帕利哌酮缓释片治疗精神分裂症的临床疗效及资源利用情况:国际抗精神病药物纵向药物流行病学登记研究(PILAR)
Curr Med Res Opin. 2014 Jul;30(7):1279-89. doi: 10.1185/03007995.2014.898630. Epub 2014 Mar 19.
8
Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First-Episode Schizophrenia Patients.长效棕榈酸帕利哌酮抗精神病药物治疗青少年首发精神分裂症患者有效性及耐受性的回顾性分析
J Child Adolesc Psychopharmacol. 2019 Apr;29(3):197-204. doi: 10.1089/cap.2018.0044. Epub 2019 Feb 13.
9
Effects of paliperidone extended release on functioning level and symptoms of patients with recent onset schizophrenia: An open-label, single-arm, flexible-dose, 12-months follow-up study.帕利哌酮缓释片对近期起病精神分裂症患者功能水平及症状的影响:一项开放标签、单臂、灵活剂量、12个月随访研究。
Nord J Psychiatry. 2015 Aug;69(6):426-32. doi: 10.3109/08039488.2014.996252. Epub 2014 Dec 31.
10
Effects of paliperidone extended release on the symptoms and functioning of schizophrenia.帕利哌酮缓释片对精神分裂症症状及功能的影响。
BMC Clin Pharmacol. 2012 Jan 6;12:1. doi: 10.1186/1472-6904-12-1.

引用本文的文献

1
Long-Term Symptomatic and Functional Remission with Paliperidone Palmitate 6-Monthly Treatment in Schizophrenia: A 3-Year Post-Hoc Analysis.使用棕榈酸帕利哌酮每月一次治疗精神分裂症的长期症状缓解和功能改善:一项为期3年的事后分析
Neuropsychiatr Dis Treat. 2025 Jun 18;21:1203-1214. doi: 10.2147/NDT.S523687. eCollection 2025.
2
Biological Methods for Diagnosing Depressive Symptoms in Patients with Schizophrenia: A Narrative Review.诊断精神分裂症患者抑郁症状的生物学方法:一项叙述性综述。
Consort Psychiatr. 2024 Sep 26;5(3):31-41. doi: 10.17816/CP15525. eCollection 2024.
3
Exploring the association between brain-derived neurotrophic factor levels and longitudinal psychopathological and cognitive changes in Sardinian psychotic patients.

本文引用的文献

1
Neurobiological Divergence of the Positive and Negative Schizophrenia Subtypes Identified on a New Factor Structure of Psychopathology Using Non-negative Factorization: An International Machine Learning Study.基于非负因子分解的精神病理学新因子结构识别的阳性和阴性精神分裂症亚型的神经生物学差异:一项国际机器学习研究。
Biol Psychiatry. 2020 Feb 1;87(3):282-293. doi: 10.1016/j.biopsych.2019.08.031. Epub 2019 Sep 23.
2
Resilience and recovery style: a retrospective study on associations among personal resources, symptoms, neurocognition, quality of life and psychosocial functioning in psychotic patients.恢复力与恢复方式:一项关于精神病患者个人资源、症状、神经认知、生活质量及心理社会功能之间关联的回顾性研究
Psychol Res Behav Manag. 2019 May 29;12:385-395. doi: 10.2147/PRBM.S205424. eCollection 2019.
3
探讨脑源性神经营养因子水平与撒丁岛精神病患者纵向心理病理和认知变化之间的关系。
Eur Psychiatry. 2022 Oct 25;65(1):e71. doi: 10.1192/j.eurpsy.2022.2333.
4
Real-World Functioning in Psychiatric Outpatients: Predictive Factors.精神科门诊患者的现实世界功能:预测因素。
J Clin Med. 2022 Jul 28;11(15):4400. doi: 10.3390/jcm11154400.
5
Participant Engagement and Symptom Improvement: Aripiprazole Tablets with Sensor for the Treatment of Schizophrenia.参与者参与度与症状改善:含传感器的阿立哌唑片治疗精神分裂症
Patient Prefer Adherence. 2022 Jul 28;16:1805-1817. doi: 10.2147/PPA.S362889. eCollection 2022.
6
Comparison of Efficacy and Safety Between Low-Dose Ziprasidone in Combination With Sertraline and Ziprasidone Monotherapy for Treatment-Resistant Patients With Acute Exacerbation Schizophrenia: A Randomized Controlled Trial.低剂量齐拉西酮联合舍曲林与齐拉西酮单药治疗难治性急性加重期精神分裂症患者的疗效与安全性比较:一项随机对照试验
Front Pharmacol. 2022 Apr 26;13:863588. doi: 10.3389/fphar.2022.863588. eCollection 2022.
Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia.将 PANSS 阴性症状评分与临床总体印象量表相联系:理解精神分裂症中的阴性症状评分。
Neuropsychopharmacology. 2019 Aug;44(9):1589-1596. doi: 10.1038/s41386-019-0363-2. Epub 2019 Mar 5.
4
A naturalistic study on the relationship among resilient factors, psychiatric symptoms, and psychosocial functioning in a sample of residential patients with psychosis.一项针对住院精神病患者样本中复原力因素、精神症状和心理社会功能之间关系的自然主义研究。
Psychol Res Behav Manag. 2018 Apr 10;11:123-131. doi: 10.2147/PRBM.S159571. eCollection 2018.
5
Consensus five factor PANSS for evaluation of clinical remission: effects on functioning and cognitive performances.用于评估临床缓解的一致性五因素阳性和阴性症状量表:对功能和认知表现的影响
Schizophr Res Cogn. 2014 Dec 8;1(4):187-192. doi: 10.1016/j.scog.2014.11.001. eCollection 2014 Dec.
6
Rehabilitation Interventions to Promote Recovery from Schizophrenia: A Systematic Review.促进精神分裂症康复的康复干预措施:一项系统综述。
Front Psychiatry. 2017 Jun 12;8:100. doi: 10.3389/fpsyt.2017.00100. eCollection 2017.
7
The relationships of personal resources with symptom severity and psychosocial functioning in persons with schizophrenia: results from the Italian Network for Research on Psychoses study.精神分裂症患者个人资源与症状严重程度及心理社会功能的关系:来自意大利精神病研究网络研究的结果。
Eur Arch Psychiatry Clin Neurosci. 2017 Jun;267(4):285-294. doi: 10.1007/s00406-016-0710-9. Epub 2016 Jul 6.
8
Determinants of different aspects of everyday outcome in schizophrenia: The roles of negative symptoms, cognition, and functional capacity.精神分裂症日常结局不同方面的决定因素:阴性症状、认知及功能能力的作用。
Schizophr Res. 2015 Jun;165(1):76-82. doi: 10.1016/j.schres.2015.03.033. Epub 2015 Apr 11.
9
Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8 years later.精神分裂症近期发病后第一年及8年后的阴性症状与功能状况。
Schizophr Res. 2015 Feb;161(2-3):407-13. doi: 10.1016/j.schres.2014.10.043. Epub 2014 Dec 8.
10
The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia.疾病相关变量、个人资源和与环境相关因素对精神分裂症患者现实生活功能的影响。
World Psychiatry. 2014 Oct;13(3):275-87. doi: 10.1002/wps.20167.